Form 4: Century Therapeutics' Officer Adrienne Farid Reports Stock and Option Grants

Adrienne Farid, Chief Operations Officer of Century Therapeutics, reports the acquisition of stock and option grants.

Summary

• Adrienne Farid, Chief Operations Officer of Century Therapeutics, filed a Form 4 with the SEC.
• The filing reports the grant of 24,000 restricted stock units (RSUs) and an option to purchase 146,000 shares of common stock on March 7, 2024.
• The RSUs vest 25% on March 7, 2025, and the remaining 75% vest quarterly over the following three years, contingent upon continued service.
• The stock options vest 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, also subject to continued service.
• Following the reported transactions, Farid beneficially owns 138,149 shares of common stock and options to purchase 146,000 shares.
• A power of attorney was executed on March 11, 2024, authorizing Brent Pfeiffenberger, Douglas Carr, and Gregory Russotti to act on Farid's behalf for Section 16 filings.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, suggesting a stable and incentivized management team. The sentiment is neutral to positive.

Positives

• The grant of RSUs and stock options to the COO aligns her interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company's long-term success.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a focus on long-term value creation and retention of key personnel.

Industry Context

Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain talent, aligning employee incentives with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• Vesting schedules are typically structured to incentivize long-term performance and retention, often spanning several years.
• The size of the grant is likely determined by a number of factors including the executive's role, performance, and the company's overall compensation strategy.
• Comparable companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates